Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1200.75.10102 Boehringer Ingelheim Investigational Site
1269
mi
from
Santa Maria, CA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1200.75.10102 Boehringer Ingelheim Investigational Site
1269
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.1.5807 Boehringer Ingelheim Investigational Site
1135
mi
from
Upland, CA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.1.5807 Boehringer Ingelheim Investigational Site
1135
mi
from
Upland, CA
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1218.64.10018 Boehringer Ingelheim Investigational Site
1306
mi
from
Pembroke Pines, FL
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1218.64.10018 Boehringer Ingelheim Investigational Site
1306
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1199.15.10027 Boehringer Ingelheim Investigational Site
1117
mi
from
Tampa, FL
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1199.15.10027 Boehringer Ingelheim Investigational Site
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
Boehringer Ingelheim Investigational Site
610
mi
from
Chicago, IL
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Boehringer Ingelheim Investigational Site
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1237.5.01028 Boehringer Ingelheim Investigational Site
1135
mi
from
Columbia, MD
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1237.5.01028 Boehringer Ingelheim Investigational Site
1135
mi
from
Columbia, MD
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.1.5811 Boehringer Ingelheim Investigational Site
1034
mi
from
Cumberland, MD
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.1.5811 Boehringer Ingelheim Investigational Site
1034
mi
from
Cumberland, MD
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
205.452.01170 Boehringer Ingelheim Investigational Site
1405
mi
from
Worcester, MA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
205.452.01170 Boehringer Ingelheim Investigational Site
1405
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1160.129.32748 Boehringer Ingelheim Investigational Site
737
mi
from
Grand Rapids, MI
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1160.129.32748 Boehringer Ingelheim Investigational Site
737
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
Boehringer Ingelheim Investigational Site
262
mi
from
Omaha, NE
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Boehringer Ingelheim Investigational Site
262
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
205.452.01046 Boehringer Ingelheim Investigational Site
1276
mi
from
Toms River, NJ
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
205.452.01046 Boehringer Ingelheim Investigational Site
1276
mi
from
Toms River, NJ
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1218.61.01029 Boehringer Ingelheim Investigational Site
1287
mi
from
Brooklyn, NY
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1218.61.01029 Boehringer Ingelheim Investigational Site
1287
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
Boehringer Ingelheim Investigational Site
958
mi
from
Charlotte, NC
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Boehringer Ingelheim Investigational Site
958
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
205.452.01309 Boehringer Ingelheim Investigational Site
746
mi
from
Dayton, OH
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
205.452.01309 Boehringer Ingelheim Investigational Site
746
mi
from
Dayton, OH
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1218.75.030 Boehringer Ingelheim Investigational Site
467
mi
from
Memphis, TN
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1218.75.030 Boehringer Ingelheim Investigational Site
467
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1200.71.1002 Boehringer Ingelheim Investigational Site
619
mi
from
Nashville, TN
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1200.71.1002 Boehringer Ingelheim Investigational Site
619
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1218.74.01105 Boehringer Ingelheim Investigational Site
334
mi
from
Carrollton, TX
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1218.74.01105 Boehringer Ingelheim Investigational Site
334
mi
from
Carrollton, TX
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1200.32.2609 Boehringer Ingelheim Investigational Site
688
mi
from
Corpus Christi, TX
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1200.32.2609 Boehringer Ingelheim Investigational Site
688
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
Boehringer Ingelheim Investigational Site
569
mi
from
Houston, TX
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Boehringer Ingelheim Investigational Site
569
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
205.452.01116 Boehringer Ingelheim Investigational Site
321
mi
from
McKinney, TX
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
205.452.01116 Boehringer Ingelheim Investigational Site
321
mi
from
McKinney, TX
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.1.5795 Boehringer Ingelheim Investigational Site
907
mi
from
Beckley, WV
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.1.5795 Boehringer Ingelheim Investigational Site
907
mi
from
Beckley, WV
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.1.5727 Boehringer Ingelheim Investigational Site
856
mi
from
Glendale, AZ
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.1.5727 Boehringer Ingelheim Investigational Site
856
mi
from
Glendale, AZ
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.4.0303 Boehringer Ingelheim Investigational Site
4681
mi
from
Kortrijk,
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.4.0303 Boehringer Ingelheim Investigational Site
4681
mi
from
Kortrijk,
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Central Research Associates, Inc
683
mi
from
Birmingham, AL
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Central Research Associates, Inc
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Core Orthopaedic Medical Center
1141
mi
from
Encinitas, CA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Core Orthopaedic Medical Center
1141
mi
from
Encinitas, CA
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Artemis Institute for Clinical Research
1139
mi
from
San Diego, CA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Artemis Institute for Clinical Research
1139
mi
from
San Diego, CA
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Westlake Medical Research
1199
mi
from
Thousand Oaks, CA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Westlake Medical Research
1199
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Coastal Carolina Center at Lowcountry Orthopaedics
1051
mi
from
North Charleston, SC
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Coastal Carolina Center at Lowcountry Orthopaedics
1051
mi
from
North Charleston, SC
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Tekton Research
517
mi
from
Austin, TX
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Tekton Research
517
mi
from
Austin, TX
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Northwest Clinical Research Center
1402
mi
from
Bellevue, WA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Northwest Clinical Research Center
1402
mi
from
Bellevue, WA
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Healthcare Research Netword
602
mi
from
Blue Island, IL
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Healthcare Research Netword
602
mi
from
Blue Island, IL
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Heartland Research Associates, LLC
32
mi
from
Wichita, KA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Heartland Research Associates, LLC
32
mi
from
Wichita, KA
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Arthritis Treatment Center
1105
mi
from
Frederick, MD
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Arthritis Treatment Center
1105
mi
from
Frederick, MD
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Healthcare Network Research
410
mi
from
Hazelwood, MO
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Healthcare Network Research
410
mi
from
Hazelwood, MO
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
St. Joseph Heritage
1154
mi
from
Fullerton, CA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
St. Joseph Heritage
1154
mi
from
Fullerton, CA
Click here to add this to my saved trials
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/19/2017
Drug Studies America
786
mi
from
Marietta, GA
AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/19/2017
Drug Studies America
786
mi
from
Marietta, GA
Click here to add this to my saved trials
Continuum™ Metal Bearing System in Total Hip Arthroplasty
Continuum™ Metal Bearing System in Total Hip Arthroplasty- A Multi-center, Prospective, Non-controlled Post Market Surveillance Study
Status: Enrolling
Updated:  12/19/2017
Saint Davids Medical Center
515
mi
from
Austin, TX
Continuum™ Metal Bearing System in Total Hip Arthroplasty
Continuum™ Metal Bearing System in Total Hip Arthroplasty- A Multi-center, Prospective, Non-controlled Post Market Surveillance Study
Status: Enrolling
Updated: 12/19/2017
Saint Davids Medical Center
515
mi
from
Austin, TX
Click here to add this to my saved trials
Continuum™ Metal Bearing System in Total Hip Arthroplasty
Continuum™ Metal Bearing System in Total Hip Arthroplasty- A Multi-center, Prospective, Non-controlled Post Market Surveillance Study
Status: Enrolling
Updated:  12/19/2017
Jokilaakson terveys oy
4857
mi
from
Jämsä,
Continuum™ Metal Bearing System in Total Hip Arthroplasty
Continuum™ Metal Bearing System in Total Hip Arthroplasty- A Multi-center, Prospective, Non-controlled Post Market Surveillance Study
Status: Enrolling
Updated: 12/19/2017
Jokilaakson terveys oy
4857
mi
from
Jämsä,
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
1167
mi
from
Glendale, AZ
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
1167
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
1167
mi
from
Glendale, AZ
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
1167
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
841
mi
from
Mesa, AZ
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
841
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
1162
mi
from
Huntington Beach, CA
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
1162
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
1167
mi
from
Lakewood, CA
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
1167
mi
from
Lakewood, CA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
680
mi
from
Granger, IN
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
680
mi
from
Granger, IN
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
643
mi
from
Indianapolis, IN
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
484
mi
from
Monroe, LA
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
484
mi
from
Monroe, LA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
484
mi
from
Monroe, LA
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
484
mi
from
Monroe, LA
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
561
mi
from
Tupelo, MS
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
561
mi
from
Tupelo, MS
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
418
mi
from
Saint Louis, MO
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/20/2017
Clinical Research Facility
418
mi
from
Saint Louis, MO
A Study of Golimumab in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/20/2017
Clinical Research Facility
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials